Cinclus Pharma Holding AB

As of June 30, 2026, Cinclus Pharma Holding AB carries a market capitalization of 511.92M, placing it among publicly traded companies globally. Its enterprise value stands at 178.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cinclus Pharma Holding AB's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Cinclus Pharma Holding AB has 46.54M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 14.55, and the price-to-book ratio stands at 2.53.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.08 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 178.67M versus a market cap of 511.92M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cinclus Pharma Holding AB maintains a current ratio of 2.30, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Cinclus Pharma Holding AB posted a negative return on equity (ROE) of -79.92, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -51.47, reflecting losses generated across the asset base. The company generates approximately 1.74M in revenue per employee across its workforce of 20.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Cinclus Pharma Holding AB recorded 69,000.00 in income tax expense. The company reported a pretax loss of -269.31M and -269.38M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Cinclus Pharma Holding AB's stock has declined approximately 24.87% over the past 52 weeks. The 50-day moving average sits at 12.63, while the 200-day moving average is 14.01.

Over the twelve months ended June 30, 2026, Cinclus Pharma Holding AB generated 35.18M in revenue and converted that into -269.38M in net income, yielding earnings per share of -5.79. EBITDA reached -288.70M, while operating income came in at -292.02M.

As of June 30, 2026, Cinclus Pharma Holding AB holds 387.92M in cash and equivalents against 54.68M in total debt, resulting in a net debt position of -339.61M. Total book value stands at 202.70M, with working capital of 235.55M providing operational flexibility.

Cinclus Pharma Holding AB produced -278.63M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.16M in capital expenditures, free cash flow totaled -279.79M - equivalent to -6.01 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -830.12 and net profit margin of -765.76 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -54.63: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -15.12, meaning Cinclus Pharma Holding AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Cinclus Pharma Holding AB has an Altman Z-Score of -3.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.